
2025 ESC/EAS update: where ezetimibe, bempedoic acid, PCSK9 drugs and inclisiran fit
A shared graphic summarizes the 2025 ESC/EAS dyslipidaemia guideline update on add-on LDL-lowering after statins. Ezetimibe is the first oral add-on, bempedoic acid suits statin intolerance, PCSK9 antibodies give the biggest reductions in very-high-risk patients, and inclisiran offers twice-yearly dosing for adherence.
